UBS AM’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

UBS AM’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-48,885	Closed	-$3.19M	–	2810
2018 Q1	$3.19M	Buy	48,885 +47,515	+3,468%	+$3.37M	﹤0.01%	1288
2017 Q4	$100K	Hold	1,370	–	–	﹤0.01%	2400
2017 Q3	$126K	Hold	1,370	–	–	﹤0.01%	2341
2017 Q2	$90.6K	Hold	1,370	–	–	﹤0.01%	2349
2017 Q1	$297K	Buy	+1,370	New	+$196K	﹤0.01%	2018
2016 Q4	–	Sell	-1,203	Closed	-$163K	–	2687
2016 Q3	$163K	Hold	1,203	–	–	﹤0.01%	2508
2016 Q2	$122K	Sell	1,203 -22,223	-95%	-$2.75M	﹤0.01%	2563
2016 Q1	$3.84M	Sell	23,426 -88	-0.4%	-$17.8K	﹤0.01%	1108
2015 Q4	$7.7M	Hold	23,514	–	–	0.01%	928
2015 Q3	$7.58M	Buy	23,514 +88	+0.4%	+$38.7K	0.01%	937
2015 Q2	$9.33M	Buy	23,426 +22,456	+2,315%	+$9.54M	0.01%	911
2015 Q1	$478K	Buy	970 +33	+4%	+$12.8K	﹤0.01%	1995
2014 Q4	$335K	Buy	+937	New	+$279K	﹤0.01%	2156
2014 Q2	–	Sell	-28,538	Closed	-$7.29M	–	2591
2014 Q1	$7.29M	Buy	28,538 +3,144	+12%	+$961K	0.01%	943
2013 Q4	$5.03M	Buy	+25,394	New	+$4.52M	0.01%	1009

Other funds holding LUMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS AM's LUMO Position: Q2 2018 in Review

UBS AM sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2018, closing a stake of 48,885 shares — an estimated $3.19M sold.

UBS AM first reported a position in LUMO in Q4 2013 and held it in 15 quarters. The position peaked at $9.33M in Q2 2015. 106 funds tracked by Wall St. Rank hold LUMO as of Q2 2018.

UBS AM reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
UBS AM sold 48,885 Lumos Pharma, Inc. Common Stock shares in Q2 2018, an estimated $3.19M.
UBS AM first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2013 and held it in 15 quarters.
UBS AM's Lumos Pharma, Inc. Common Stock position peaked at $9.33M in Q2 2015.
106 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2018.

Based on UBS AM's 13F filing for Q2 2018, filed 14 Aug 2018.